Summary

BioFluidica is a privately held biotechnology company that has developed a revolutionary liquid biopsy platform allowing for the isolation and analysis of all liquid biopsy biomarkers, including rare cells, EVs (exosomes), and cfDNA, on one fully automated platform. The Biofluidica platform has been clinically tested on nine different cancer and prenatal patient samples and is currently used for a large variety of research applications to advance the field of liquid biopsy. The ultralow sensitivity expands the capability of current liquid biopsy applications. We are expert consultants in exosome isolation, fetal cell isolation, CTC isolation, and next-generation liquid biopsy.We develop and launch innovative scientific instruments, reagents, and software systems designed to provide exceptional value for scientists, clinicians, and patients

Advantage

ISOLATE RARE CELLS AND EXOSOMES – CTCs, TROPHOBLASTS, EVs

BioFluidica has created LiquidScan® as a unique fully automated system for isolating and enriching rare cells and exosomes from liquid biopsy samples. The system uses a microfluidic chip surfaced with antibodies targeting biomarkers of interest, creating the future of liquid biopsy

Application

CLINICAL RESEARCH

OvarianColorectalEndometrialLungPancreaticProstateBladderLeiomyosarcoma

CholangiocarcinomaMultiple MyelomaAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia

PrenatalStrokeSARS-CoV-2 Detection

Detailed Specifications